卡非佐米相关方案治疗复发难治性多发性骨髓瘤的早期效果及不良反应的临床观察  

Clinical Observation of Early Efficacy and Adverse Reactions of Carfilzomib Related Regimen in the Treatment of Relapsed Refractory Multiple Myeloma

作　　者：陈丹宁 张华[1] 李虎生[1] 叶光剑 Chen Danning;Zhang Hua;Li Husheng;Ye Guangjian(Department of Hematology,Yulin Red Cross Hospital,Yulin 537000,Guangxi Zhuang Autonomous Region,China)

机构地区：[1]玉林市红十字会医院血液内科,广西壮族自治区玉林537000

出　　处：《中外医药研究》2024年第5期6-8,共3页JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH

摘　　要：目的:探究卡非佐米相关方案治疗复发难治性多发性骨髓瘤(RRMM)的早期效果及不良反应。方法:回顾性分析2021年10月—2023年9月于玉林市红十字会医院接受卡非佐米治疗的32例RRMM患者的临床资料。6例采用苯达莫司汀、卡非佐米、地塞米松治疗方案,4例采用卡非佐米、地塞米松治疗方案,12例采用卡非佐米、地塞米松、来那度胺治疗方案,10例采用卡非佐米、地塞米松、泊马度胺治疗方案。评估患者临床疗效,统计不良反应发生情况。结果:32例患者均接受≥2个周期的治疗方案,中位治疗3(2,5)个周期,完全缓解2例,非常好的部分缓解7例,部分缓解8例,疾病稳定11例,疾病进展4例,客观缓解率为53.13%。血液学不良反应以中性粒细胞减少(28.12%)最常见,其次为贫血(21.87%)、血小板减少(15.62%);非血液学不良反应以疲劳(31.25%)最常见,其次为腹泻(21.87%)、恶心(12.5%)、心律失常(9.37%)。结论:初步观察到卡非佐米相关方案在治疗RRMM患者时具有良好的临床疗效和用药安全性。Objective:To investigate the early efficacy and adverse reactions of carfilzomib related regimen in the treatment of relapsed refractory multiple myeloma(RRMM).Methods:The clinical data of thirty-two patients with RRMM who received carfilzomib in Yulin Red Cross Hospital from October 2021 to September 2023 were retrospectively analyzed.Six cases were treated with bendamustine,carfilzomib and dexamethasone.Four cases were treated with carfilzomib and dexamethasone.Twelve cases were treated with carfilzomib,dexamethasone and lenalidomide.Ten cases were treated with carfilzomib,dexamethasone and pomadomide.The clinical efficacy of the patients was evaluated and the incidence of adverse reactions was counted.Results:All 32 patients received≥2 cycles of treatment,with a median of 3(2,5)cycles of treatment,2 patients had complete response,7 patients had very good partial response,8 patients had partial response,11 patients had stable disease,and 4 patients had disease progression,with an objective response rate of 53.13%.Neutropenia(28.12%)was the most common hematological adverse reaction,followed by anemia(21.87%)and thrombocytopenia(15.62%);fatigue(31.25%)was the most common non-hematological adverse reaction,followed by diarrhea(21.87%),nausea(12.5%)and arrhythmia(9.37%).Conclusion:It is preliminarily observed that carfilzomib related regimen had good clinical efficacy and drug safety in the treatment of RRMM patients.

关 键 词：卡非佐米 复发难治性多发性骨髓瘤 疗效 

分 类 号：R733.3[医药卫生—肿瘤]